Articles & Resources

Insights From Alkemi

Our deepest insights on evidence planning, HEOR, market access and patient access strategies.

Tags
RWE
HTA
ICER
Value & Access
Market Shaping
FDA
Market Access
Rare Disease
Breakthrough
IRA
HEOR
Subscribe to Our Newsletter

Subscribe our newsletter to receive the latest blogs, case studies and publications.

Subscribe
image of a doctor talking to a patient
November 25, 2025

Planning RWE After Launch is Like Planning a Clinical Trial After Enrollment

Read More
image of a doctor talking to a patient
November 4, 2025

You Missed the Endpoint Meeting - Now What?

Read More
image of a doctor talking to a patient
October 7, 2025

When the Commercial Team Comes Knocking: The 5-Day Evidence Crisis Protocol

Read More
image of a doctor talking to a patient
August 29, 2025

The Healthcare Spending Paradox: What 17% of GDP Means for Innovation Leaders

Read More
image of a doctor talking to a patient
July 31, 2025

From Models to Meaning: The Art of Making HEOR Matter

Read More
image of a doctor talking to a patient
June 18, 2025

The "Too Late" Test: A Framework for Evidence-Ready Launch Planning

Read More
image of a doctor talking to a patient
May 27, 2025

Why Good Evidence Still Gets a “No”: A Practical Guide to Value Communication Tools

Read More
image of a doctor talking to a patient
April 18, 2025

A Seat at the Table: Incorporating Patient Perspectives in Product Development

Read More
image of a doctor talking to a patient
March 20, 2025

The Road Less Funded: Why Biotech Innovation is Stuck - And How to Fix It

Read More
image of a doctor talking to a patient
March 11, 2025

Value Teams Under Fire: A Framework for Survival

Read More
image of a doctor talking to a patient
March 11, 2025

Regulatory Win to Commercial Disaster: Mind the Evidence Gap

Read More
image of a doctor talking to a patient
February 3, 2025

Value and Access Isn’t a Department - It’s a Business Model

Read More
image of a doctor talking to a patient
November 22, 2024

Your Market Access Playbook is Dead. Now What?

Read More